docetaxel: clinical use

Prescribing considerations

• Confine administration to specialist cytotoxic-chemotherapy units under an experienced cancer physician.
• Use indicated corticosteroid premedication unless contraindicated to reduce fluid retention and hypersensitivity.
• Assess hepatic function carefully because reduced clearance increases severe-toxicity risk.
• Consider regimen-specific growth-factor prophylaxis and supportive care according to individual neutropenia risk.
• Review CYP3A4 inhibitors and the clinical relevance of the formulation's ethanol content.
• Closely assess early gastrointestinal toxicity, pulmonary symptoms, neuropathy, skin reactions and fluid retention.

Contraindications and cautions

• Hypersensitivity to docetaxel or any selected-product excipient
• Baseline neutrophil count below 1.5 × 10⁹/L
• Severe hepatic impairment
• Any contraindication applying to a medicine used in the combination regimen

Monitoring

• Full blood count before treatment and during therapy, particularly neutrophils
• Liver-function tests at baseline and before subsequent treatment
• Observation for hypersensitivity during infusion
• Clinical assessment for infection, enterocolitis, peripheral neurotoxicity, fluid retention and severe skin reactions
• Prompt investigation of new or worsening respiratory symptoms
• Cardiac assessment where clinically indicated, particularly with trastuzumab or previous anthracycline exposure

Clinical pharmacology

Docetaxel is a highly protein-bound taxane that stabilises microtubules and prevents their normal disassembly. It is metabolised mainly through CYP3A4-mediated oxidation and eliminated predominantly through the faeces as metabolites; hepatic impairment can reduce clearance.

Formulation and product differences

• The selected Hospira product is a clear, colourless to pale-yellow concentrate requiring dilution before intravenous infusion.
• It contains ethanol, macrogol 300, polysorbate 80 and citric acid; excipients and preparation instructions must be checked against the selected product.
• Preparation and handling require trained personnel, cytotoxic precautions and appropriate disposal procedures.

Solution for infusion

Route: Intravenous

Strengths: 10 mg/mL